Canadian Cancer Trials Group Bulletins

Trial Management Group


Shortage of Commercially-Available Cytarabine

It has recently come to the attention of Canadian Cancer Trials Group that certain centres participating in trials ALC.1, ALC.2, AL.5 & LY.12 may be experiencing a shortage in the commercial supply of cytarabine of unknown duration.

Therefore, centres participating on ALC.1, ALC.2, AL.5 and LY.12 should:

 Ensure adequate supplies are available for patients already randomized to these trials. If there is insufficient cytarabine for patients already randomized to these trials, please consult with Canadian Cancer Trials Group for further instructions on how to best treat these patients and document this treatment.

 Ensure adequate supplies are available for patients about to be randomized. Should there not be enough to sufficiently treat these patients according to the study protocol, randomization to these trials should be halted at your site pending availability of this agent.

Any questions about this should be directed to:

Pat Smith
ALC.1, ALC.2, & AL.5 Study Coordinator
psmith@ctg.queensu.ca

Marina Djurfeldt
LY.12 Study Coordinator
mdjurfeldt@ctg.queensu.ca